Browsing Clinical Studies by author "Pearson, Alex"
Now showing items 1-3 of 3
-
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)<h4>Background</h4>Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of ... -
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; Proszek, P; Hubank, M; Dowsett, M; Dodson, A; Daley, F; Kriplani, D; Gevensleben, H; Davies, HR; Degasperi, A; Roylance, R; Chan, S; Tutt, A; Skene, A; Evans, A; Bliss, JM; Nik-Zainal, S; Turner, NC (2020-05-29)Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ... -
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Pascual, J; Lim, JSJ; Macpherson, IR; Armstrong, AC; Ring, A; Okines, AFC; Cutts, RJ; Herrera-Abreu, MT; Garcia-Murillas, I; Pearson, A; Hrebien, S; Gevensleben, H; Proszek, PZ; Hubank, M; Hills, M; King, J; Parmar, M; Prout, T; Finneran, L; Malia, J; Swales, KE; Ruddle, R; Raynaud, FI; Turner, A; Hall, E; Yap, TA; Lopez, JS; Turner, NC (2020-09-21)Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in <i>PIK3CA</i>-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet ...